vs

Side-by-side financial comparison of CULLEN/FROST BANKERS, INC. (CFR) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

CULLEN/FROST BANKERS, INC. is the larger business by last-quarter revenue ($580.9M vs $321.1M, roughly 1.8× MADRIGAL PHARMACEUTICALS, INC.). CULLEN/FROST BANKERS, INC. runs the higher net margin — 28.6% vs -18.2%, a 46.9% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 8.3%). CULLEN/FROST BANKERS, INC. produced more free cash flow last quarter ($127.3M vs $-133.8M).

Frost Bank is an American bank based in San Antonio that is chartered in Texas, with 200 branches and 1,750 automated teller machines in the state. It is the primary subsidiary of Cullen/Frost Bankers, Inc., a bank holding company. It is one of the 60 largest banks of the country by total assets.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

CFR vs MDGL — Head-to-Head

Bigger by revenue
CFR
CFR
1.8× larger
CFR
$580.9M
$321.1M
MDGL
Growing faster (revenue YoY)
MDGL
MDGL
+202.5% gap
MDGL
210.8%
8.3%
CFR
Higher net margin
CFR
CFR
46.9% more per $
CFR
28.6%
-18.2%
MDGL
More free cash flow
CFR
CFR
$261.2M more FCF
CFR
$127.3M
$-133.8M
MDGL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CFR
CFR
MDGL
MDGL
Revenue
$580.9M
$321.1M
Net Profit
$166.3M
$-58.6M
Gross Margin
Operating Margin
34.1%
-18.6%
Net Margin
28.6%
-18.2%
Revenue YoY
8.3%
210.8%
Net Profit YoY
7.4%
1.4%
EPS (diluted)
$2.56
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CFR
CFR
MDGL
MDGL
Q4 25
$580.9M
$321.1M
Q3 25
$567.3M
$287.3M
Q2 25
$546.9M
$212.8M
Q1 25
$540.2M
$137.3M
Q4 24
$536.3M
$103.3M
Q3 24
$518.0M
$62.2M
Q2 24
$507.9M
Q1 24
$501.4M
$0
Net Profit
CFR
CFR
MDGL
MDGL
Q4 25
$166.3M
$-58.6M
Q3 25
$174.4M
$-114.2M
Q2 25
$157.0M
$-42.3M
Q1 25
$150.9M
$-73.2M
Q4 24
$154.9M
$-59.4M
Q3 24
$146.5M
$-107.0M
Q2 24
$145.5M
Q1 24
$135.7M
$-147.5M
Gross Margin
CFR
CFR
MDGL
MDGL
Q4 25
Q3 25
Q2 25
Q1 25
96.7%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
CFR
CFR
MDGL
MDGL
Q4 25
34.1%
-18.6%
Q3 25
36.7%
-39.7%
Q2 25
34.1%
-22.2%
Q1 25
33.2%
-57.8%
Q4 24
34.3%
-64.8%
Q3 24
33.8%
-187.1%
Q2 24
34.5%
Q1 24
32.2%
Net Margin
CFR
CFR
MDGL
MDGL
Q4 25
28.6%
-18.2%
Q3 25
30.7%
-39.8%
Q2 25
28.7%
-19.9%
Q1 25
27.9%
-53.4%
Q4 24
28.9%
-57.5%
Q3 24
28.3%
-172.0%
Q2 24
28.6%
Q1 24
27.1%
EPS (diluted)
CFR
CFR
MDGL
MDGL
Q4 25
$2.56
$-2.55
Q3 25
$2.67
$-5.08
Q2 25
$2.39
$-1.90
Q1 25
$2.30
$-3.32
Q4 24
$2.36
$-2.50
Q3 24
$2.24
$-4.92
Q2 24
$2.21
Q1 24
$2.06
$-7.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CFR
CFR
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$198.7M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$4.6B
$602.7M
Total Assets
$53.0B
$1.3B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CFR
CFR
MDGL
MDGL
Q4 25
$198.7M
Q3 25
$295.7M
Q2 25
$186.2M
Q1 25
$183.6M
Q4 24
$100.0M
Q3 24
$232.7M
Q2 24
Q1 24
$622.5M
Total Debt
CFR
CFR
MDGL
MDGL
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$117.1M
Q2 24
Q1 24
$116.1M
Stockholders' Equity
CFR
CFR
MDGL
MDGL
Q4 25
$4.6B
$602.7M
Q3 25
$4.5B
$625.7M
Q2 25
$4.2B
$696.0M
Q1 25
$4.1B
$710.6M
Q4 24
$3.9B
$754.4M
Q3 24
$4.1B
$777.2M
Q2 24
$3.7B
Q1 24
$3.6B
$850.8M
Total Assets
CFR
CFR
MDGL
MDGL
Q4 25
$53.0B
$1.3B
Q3 25
$52.5B
$1.4B
Q2 25
$51.4B
$1.0B
Q1 25
$52.0B
$996.6M
Q4 24
$52.5B
$1.0B
Q3 24
$51.0B
$1.1B
Q2 24
$48.8B
Q1 24
$49.5B
$1.1B
Debt / Equity
CFR
CFR
MDGL
MDGL
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CFR
CFR
MDGL
MDGL
Operating Cash FlowLast quarter
$274.0M
$-133.5M
Free Cash FlowOCF − Capex
$127.3M
$-133.8M
FCF MarginFCF / Revenue
21.9%
-41.7%
Capex IntensityCapex / Revenue
25.2%
0.1%
Cash ConversionOCF / Net Profit
1.65×
TTM Free Cash FlowTrailing 4 quarters
$116.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CFR
CFR
MDGL
MDGL
Q4 25
$274.0M
$-133.5M
Q3 25
$248.6M
$79.8M
Q2 25
$140.8M
$-47.1M
Q1 25
$-296.1M
$-88.9M
Q4 24
$989.5M
$-104.5M
Q3 24
$307.2M
$-67.0M
Q2 24
$129.6M
Q1 24
$488.4M
$-149.2M
Free Cash Flow
CFR
CFR
MDGL
MDGL
Q4 25
$127.3M
$-133.8M
Q3 25
$211.7M
$79.0M
Q2 25
$114.5M
Q1 25
$-337.1M
Q4 24
$861.8M
$-104.7M
Q3 24
$281.9M
$-67.8M
Q2 24
$103.0M
Q1 24
$450.3M
$-149.5M
FCF Margin
CFR
CFR
MDGL
MDGL
Q4 25
21.9%
-41.7%
Q3 25
37.3%
27.5%
Q2 25
20.9%
Q1 25
-62.4%
Q4 24
160.7%
-101.3%
Q3 24
54.4%
-109.0%
Q2 24
20.3%
Q1 24
89.8%
Capex Intensity
CFR
CFR
MDGL
MDGL
Q4 25
25.2%
0.1%
Q3 25
6.5%
0.3%
Q2 25
4.8%
0.0%
Q1 25
7.6%
0.0%
Q4 24
23.8%
0.2%
Q3 24
4.9%
1.3%
Q2 24
5.2%
Q1 24
7.6%
Cash Conversion
CFR
CFR
MDGL
MDGL
Q4 25
1.65×
Q3 25
1.43×
Q2 25
0.90×
Q1 25
-1.96×
Q4 24
6.39×
Q3 24
2.10×
Q2 24
0.89×
Q1 24
3.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CFR
CFR

Segment breakdown not available.

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons